Literature DB >> 23648307

Propafenone blocks human cardiac Kir2.x channels by decreasing the negative electrostatic charge in the cytoplasmic pore.

Irene Amorós1, Pablo Dolz-Gaitón, Ricardo Gómez, Marcos Matamoros, Adriana Barana, Marta González de la Fuente, Mercedes Núñez, Marta Pérez-Hernández, Ignacio Moraleda, Enrique Gálvez, Isabel Iriepa, Juan Tamargo, Ricardo Caballero, Eva Delpón.   

Abstract

Human cardiac inward rectifier current (IK1) is generated by Kir2.x channels. Inhibition of IK1 could offer a useful antiarrhythmic strategy against fibrillatory arrhythmias. Therefore, elucidation of Kir2.x channels pharmacology, which still remains elusive, is mandatory. We characterized the electrophysiological and molecular basis of the inhibition produced by the antiarrhythmic propafenone of the current generated by Kir2.x channels (IKir2.x) and the IK1 recorded in human atrial myocytes. Wild type and mutated human Kir2.x channels were transiently transfected in CHO and HEK-293 cells. Macroscopic and single-channel currents were recorded using the patch-clamp technique. At concentrations >1μM propafenone inhibited IKir2.x the order of potency being Kir2.3IK1>Kir2.2>Kir2.1 channels. Blockade was irrespective of the extracellular K(+) concentration whereas markedly increased when the intracellular K(+) concentration was decreased. Propafenone decreased inward rectification since at potentials positive to the K(+) equilibrium potential propafenone-induced block decreased in a voltage-dependent manner. Importantly, propafenone favored the occurrence of subconductance levels in Kir2.x channels and decreased phosphatidylinositol 4,5-bisphosphate (PIP2)-channel affinity. Blind docking and site-directed mutagenesis experiments demonstrated that propafenone bound Kir2.x channels at the cytoplasmic domain, close to, but not in the pore itself, the binding site involving two conserved Arg residues (residues 228 and 260 in Kir2.1). Our results suggested that propafenone incorporated into the cytoplasmic domain of the channel in such a way that it decreased the net negative charge sensed by K(+) ions and polyamines which, in turn, promotes the appearance of subconductance levels and the decrease of PIP2 affinity of the channels.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23648307     DOI: 10.1016/j.bcp.2013.04.023

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Class III antiarrhythmic drug dronedarone inhibits cardiac inwardly rectifying Kir2.1 channels through binding at residue E224.

Authors:  Panagiotis Xynogalos; Claudia Seyler; Daniel Scherer; Christoph Koepple; Eberhard P Scholz; Dierk Thomas; Hugo A Katus; Edgar Zitron
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-04       Impact factor: 3.000

2.  Nicotine at clinically relevant concentrations affects atrial inward rectifier potassium current sensitive to acetylcholine.

Authors:  Markéta Bébarová; Peter Matejovič; Olga Švecová; Roman Kula; Milena Šimurdová; Jiří Šimurda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-02-03       Impact factor: 3.000

Review 3.  Polyamines and potassium channels: A 25-year romance.

Authors:  Colin G Nichols; Sun-Joo Lee
Journal:  J Biol Chem       Date:  2018-10-17       Impact factor: 5.157

4.  Control of Kir channel gating by cytoplasmic domain interface interactions.

Authors:  William F Borschel; Shizhen Wang; Sunjoo Lee; Colin G Nichols
Journal:  J Gen Physiol       Date:  2017-04-07       Impact factor: 4.086

Review 5.  Cardiac potassium inward rectifier Kir2: Review of structure, regulation, pharmacology, and arrhythmogenesis.

Authors:  Louise Reilly; Lee L Eckhardt
Journal:  Heart Rhythm       Date:  2021-04-20       Impact factor: 6.343

6.  In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome.

Authors:  Dominic G Whittaker; Jules C Hancox; Henggui Zhang
Journal:  Front Physiol       Date:  2019-01-11       Impact factor: 4.566

Review 7.  Towards the Development of AgoKirs: New Pharmacological Activators to Study Kir2.x Channel and Target Cardiac Disease.

Authors:  Laura van der Schoor; Emma J van Hattum; Sophie M de Wilde; Netanja I Harlianto; Aart-Jan van Weert; Meye Bloothooft; Marcel A G van der Heyden
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.